Rebuilding surveillance to be better, stronger, faster
You’ve probably already seen the headlines: A new study posits that the cardiovascular risks of Merck’s long-withdrawn Vioxx drug could have been identified by 2001 if trial data were pooled, regularly updated, and made available for independent analysis via an almost-real-time public database. Almost as soon as the Archives of Internal Medicine study hit, Merck released a statement saying
